PepTalk
Client-side only
Library

Kisspeptin

The Puberty Peptide

Kickstarts your body's own testosterone and fertility naturally

Hormonal & NichePeptideRoute · SubQReviewed Apr 2026
01 — OVERVIEW
SYSTEMSHow Kisspeptin affects you

Restarts the reproductive hormone axis.

The master regulator of the HPG axis. Binds hypothalamic KISS1R receptors, triggering GnRH release and kicking the whole cascade of LH, FSH, and sex hormones back into gear.

LH
acute response
Onset
30–60 min
  • Used clinically to trigger ovulation in fertility treatment.
  • Restores pulsatile GnRH in hypogonadotropic hypogonadism.
  • Promising research tool for amenorrhea and delayed puberty.

Kisspeptin is the first domino in your body's hormone chain. It tells your brain to start the whole process that ends with testosterone (in men) and reproductive hormones (in women). Unlike taking testosterone directly, kisspeptin works through your body's natural system — so your body stays in control. It's being researched for fertility and low testosterone.

02 — PHARMACOKINETICS

How long it stays, how it leaves.

Half-life
30 min
Default concentration
5000 mcg
Common vial sizes
5000 mcg

Fixed dosing — not weight-adjusted. The calculator handles reconstitution math for common vial sizes so you inject the right volume every time.

03 — DOSING PROTOCOL

Three tiers, three goals.

beginner4 weeks cycle
Dose
50100 mcg
Frequency
Once daily
Cycle
4 weeks
intermediate4-8 weeks cycle
Dose
100200 mcg
Frequency
Once daily
Cycle
4-8 weeks
advanced8-12 weeks cycle
Dose
200400 mcg
Frequency
Once daily
Cycle
8-12 weeks
04 — SIDE EFFECTS

What people actually report.

  • Redness at injection spot
  • Mood changes
  • Hot flashes
05 — WARNINGS

Before you start.

  • Being actively researched for fertility treatments
  • Doesn't shut down your natural hormone production
  • May not work if your pituitary gland has issues
06 — STACKING & INTERACTIONS

No documented stacks yet.

07 — CITATIONS & Q&A

Research behind the claims.

Jayasena CN, Abbara A, Comninos AN, et al. · Journal of Clinical Investigation · 2014
First-in-human IVF study: kisspeptin-54 reliably triggered oocyte maturation with lower ovarian hyperstimulation risk than standard hCG triggers.
Abbara A, Jayasena CN, Christopoulos G, et al. · Journal of Clinical Endocrinology & Metabolism · 2015
Kisspeptin-54 safely triggered oocyte maturation in high-risk IVF patients, preventing the dangerous hyperstimulation syndrome associated with hCG.
Skorupskaite K, George JT, Anderson RA. · Human Reproduction Update · 2014
Review establishing kisspeptin as the master regulator of GnRH pulsatility and a validated clinical target for infertility and hypogonadism.

Ask anything, get cited answers.